Unzyme Laboratories announces the opening of enrollment for the PHOENIX Protocol, our Phase II clinical trial evaluating next-generation cardiovascular enhancement technologies. The study represents a significant advance in our cardiac enhancement program and offers hope for patients with limited treatment options.
About the PHOENIX Protocol
The PHOENIX Protocol evaluates an integrated cardiovascular enhancement system designed to address multiple cardiac limitations simultaneously:
- CardioCore X: Our next-generation cardiac support system
- Vasculan Enhancement: Complementary vascular optimization
- Neural-Cardiac Interface: Autonomous regulation and monitoring
This integrated approach aims to restore and exceed normal cardiac function in patients with severe heart conditions.
Who Should Apply
The PHOENIX Protocol is seeking participants who meet the following general criteria:
Inclusion Criteria
- Adults aged 35-70 years
- Diagnosis of chronic heart failure (NYHA Class II-III)
- Ejection fraction between 20-40%
- Stable on optimal medical therapy for at least 3 months
- Exhausted or ineligible for standard interventions
Exclusion Criteria
- Active cardiac device infection
- Significant valve disease requiring intervention
- Recent myocardial infarction (within 6 months)
- Severe renal or hepatic impairment
- Prior cardiac transplantation
These criteria ensure participant safety while identifying those most likely to benefit.
What Participation Involves
Participants in the PHOENIX Protocol will receive:
- Comprehensive cardiac evaluation at no cost
- The PHOENIX enhancement system if eligible
- Ongoing monitoring for 24 months
- Compensation for time and travel
The study requires approximately 12 clinic visits over two years, plus remote monitoring via our secure patient app.
Trial Locations
The PHOENIX Protocol is currently enrolling at:
Europe
- Unzyme Laboratories Evolution Center, Stockholm
- University Hospital Zürich
- Charité - Universitätsmedizin Berlin
- Hospital Clínic de Barcelona
North America
- Johns Hopkins Hospital, Baltimore
- Cleveland Clinic, Ohio
- Toronto General Hospital
How to Apply
Interested individuals should:
- Visit our clinical trials page
- Complete the preliminary eligibility questionnaire
- Provide contact information for follow-up
- Submit relevant medical records if requested
Our clinical enrollment team will review all submissions and contact potentially eligible candidates within two weeks.
Questions?
For questions about the PHOENIX Protocol, contact our clinical trials hotline or email phoenix-trial@unzyme.com.
Hope is not lost. Your heart’s best days may still be ahead.